AbbVie Inc. (ABBV)

ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.

Here's a statistic that should reshape how you think about investing: Companies that consistently raise dividends have crushed the S&P 500 by 2.5 percentage points annually since 1972. Not tech highfl...

AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical...

ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.

Dividends have quietly driven the bulk of stock market returns for over a century. While share prices grab headlines, reinvested dividends account for the majority of total returns in global equity ma...

AbbVie (ABBV -1.13%) ranks as the third-largest pharmaceutical company in the world, with a market capitalization hovering around $390 billion. It markets around a dozen blockbuster drugs, plus many o...

AbbVie (ABBV) concluded the recent trading session at $219.99, signifying a -1.18% move from its prior day's close.